![Triazines / Orphan drugs / Azacitidine / lactams / Myelodysplastic syndrome / Decitabine / Hypomethylating agent / Lenalidomide / Acute myeloid leukemia / Medicine / Oncology / Nucleosides Triazines / Orphan drugs / Azacitidine / lactams / Myelodysplastic syndrome / Decitabine / Hypomethylating agent / Lenalidomide / Acute myeloid leukemia / Medicine / Oncology / Nucleosides](https://www.pdfsearch.io/img/07ce2929df13e5cee962290ec01f32ff.jpg) Triazines Orphan drugs Azacitidine lactams Myelodysplastic syndrome Decitabine Hypomethylating agent Lenalidomide Acute myeloid leukemia Medicine Oncology Nucleosides | | Abst. No. Outcomes of Intermediate or High Risk Myelodysplastic Syndromes (MDS) Patients Post Azacitidine and/or Decitabine Treatment Failures with SGI-110, a Novel Second Generation Hypomethylating Agent (HMA)Add to Reading ListSource URL: astx.comDownload Document from Source Website File Size: 263,44 KBShare Document on Facebook
|